Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively ...
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for ...
Minoryx Therapeutics has dosed the first patient in its phase 2a TREE study, which evaluates the safety and efficacy of ...
Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...
A delivery driver has quit his job to run the length of the UK in a month for a cause close to his heart. Jack Ward, 24, from Warwickshire, was inspired by "Hardest Geezer", also known as Russ Cook, ...
What is Guillain-Barré syndrome? Guillain-Barré syndrome (GBS) is also called acute inflammatory demyelinating polyradiculoneuropathy (AIDP). It's a neurological disorder in which the body's immune ...
NGNE to update on a potential registrational phase 3 study, using NGN-401, for the treatment of patients with Rett Syndrome.
Heading the BNA2025? We've gone through the scientific program to find the sessions we think the BioTechniques audience will ...
Healthcare analysts believe that shares in rare neurological share play Neuren Pharmaceuticals are well undervalued after a ...
Stockhead on MSN15d
Neurotech receives positive opinion for orphan status in Rett Syndrome from European drug regulatorNeurotech has received positive feedback from the European Medicines Agency (EMA) on its orphan drug application for NTI164 to treat ... Read More The post Neurotech receives positive opinion for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback